Vaccine

Another week, another set of preliminary results from a Covid-19 vaccine trial. This time it is the Moderna vaccine candidate, mRNA-1273. And, to judge by the figures put out by the company this morning, it has outdone the Pfizer vaccine in its efficacy. Out of the 30,000 people involved in the phase three trial (half of whom were given the vaccine and half of whom were given a placebo), 95 went on to contract Covid-19. Of those who became infected, 90 were in the control group and only five had been given the vaccine. Eleven participants had a severe case of Covid, all of whom were in the control group.

Home Pfizer and BioNTech announced a vaccine against Covid-19 of 90 per cent efficacy from two injections three weeks apart. It was not known if it prevented transmission of the virus. The vaccine has to be stored at an ultra-low temperature of minus 80˚C. In July, the British government had bought 40 million doses, enough for a third of the population, with ten million available by the end of the year (along with access to five other vaccine candidates, totalling 340 million doses in all). The army and police planned vaccination centres. Shares in air transport went up; shares in Zoom went down. Asked whether we could say with confidence

So is this the big turning point? Markets certainly seem to think so. No sooner had news broken that the vaccine being developed by Pfizer and German firm BioNTech is 90 per cent effective, the FTSE surged by 5 per cent. Given that the US Food and Drug Administration (FDA) has suggested that any vaccine that proves to be more than 50 per cent effective could be licensed, this suggests the vaccine will go on to be approved around the world. Any vaccine that proves partly effective will be welcomed with open arms by a world which largely remains in lockdown or semi-lockdown. But does the reality live up the

Was the Oxford vaccine trial paused? Mine wasn’t. I signed up for it last week, in the 55 to 69-year-old category, and I was told on Friday that I should continue posting my swabs and attending follow-up appointments.  My friends were keen to tell me I was ‘utterly mad’ to join a trial. But I believe in vaccines. So do most anti-vaxxers, incidentally. It would be a rare adult who hadn’t benefited from childhood inoculations against polio, diphtheria, tetanus and whooping cough. My parents, who were raised in the 1930s, didn’t just believe in vaccines they rejoiced in them. When they were little it was all too common for a family to

What comes next, now that the transmission rate and prevalence of Covid-19 have fallen significantly? (Before you shout at me, yes I know there is frustration and some bemusement among scientists that illness incidence and numbers of deaths have not dropped faster in the UK, but they have nonetheless reduced significantly, if not uniformly, everywhere). There are detailed plans from the government for when and how to restart certain businesses and social activities in the coming six weeks. But there is not a clearly articulated strategy for how we are expected to live and work between now and the end of the year (and beyond). So I’ve tried to piece